Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q2 2017 · 10-Q
Revenue$2.87M$2.87M+49.8% vs Q2 2016 Net Income-$361.50K-$361.50KN/M vs Q2 2016 EPS Diluted-$0.04-$0.04no prior Q2 2016 on file Gross Profit$1,260,289+27.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived-$398,860N/M Free Cash Flowderived-$407,313N/M Margins · derivedGross margin44.0%−7.8 pt vs Q2 2016
Operating margin-12.9%+18.6 pt vs Q2 2016
Net margin-12.6%+18.3 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 1, 2017 · 32 d after period end